Supernus Pharmaceuticals Stock Price Up 7.7% on Earnings Beat (SUPN)
Supernus Pharmaceuticals (NASDAQ:SUPN) rose 7.7% during trading on Tuesday after the company announced better than expected quarterly earnings, Stock Ratings Network reports. The company traded as high as $9.51 and last traded at $8.97, with a volume of 728,296 shares trading hands. The stock had previously closed at $8.33.
The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.24. The company had revenue of $29.67 million for the quarter, compared to the consensus estimate of $19.85 million. During the same quarter in the previous year, the company posted ($0.57) earnings per share. The company’s revenue for the quarter was up 10500.0% on a year-over-year basis.
Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Supernus Pharmaceuticals in a research note on Thursday, May 15th. They now have a $9.00 price target on the stock.
The stock’s 50-day moving average is $9.70 and its 200-day moving average is $9.21. The company’s market cap is $373.4 million.
Supernus Pharmaceuticals, Inc (NASDAQ:SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.